The following is a summary of “Factors predicting local or systemic side effects related to intravesical BCG (Bacillus ...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for ... combination with the BCG vaccine in non-muscle invasive bladder cancer (NMIBC) patients ...

The FDA application is for the use of TAR-200 as a treatment for high-risk, non-muscle-invasive bladder cancer (NMIBC) that does not respond to BCG, a live bacterial vaccine that is the standard ...

Intravesical BCG remains a mainstay of treatment for intermediate and high-risk non-muscle invasive bladder cancer, however, since 2012 there has been a global BCG shortage. Various management ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Jacob Moyer discussing real-world outcomes of nadofaragene firadenovec in BCG-unresponsive ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

A vaccine kept patients free of pancreatic cancer for years, yet new reports say the NIH is advising against mentioning mRNA tech in grants.

SAN DIEGO, Calif. (Ivanhoe Newswire) - A breakthrough in bladder cancer treatment is helping to save more lives. The American Cancer Society estimates that 83,000 new cases of bladder cancer will be ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.